• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The Synergistic Neuroprotective Effects of Combined Rosuvastatin and Resveratrol Pretreatment against Cerebral Ischemia/Reperfusion Injury
It is well accepted that both rosuvastatin and resveratrol exert neuroprotective effects on cerebral ischemia/reperfusion injury through some common pathways. Resveratrol has also been demonstrated to protect against cerebral ischemia/reperfusion injury through enhancing autophagy. Thus, we hypothesized that combined rosuvastatin and resveratrol pretreatment had synergistic effects on cerebral ischemia/reperfusion injury.
Source: Journal of Stroke and Cerebrovascular Diseases - March 7, 2018 Category: Neurology Authors: Ying Liu, HongNa Yang, GuoYong Jia, Lan Li, Hui Chen, JianZhong Bi, CuiLan Wang Source Type: research

Effects of Rosuvastatin on Serum Lipids and Arteriosclerosis in Dyslipidemic Patients with Cerebral Infarction
Conclusions: Rosuvastatin at 5 mg/day significantly reduced serum levels of TC, LDL-C, non–HDL-C, and hs-CRP in dyslipidemic patients with cerebral infarction. No significant change in CAVI, max-IMT, or PS was noted after the study treatment.
Source: Journal of Stroke and Cerebrovascular Diseases - July 28, 2014 Category: Neurology Authors: Ichiro Deguchi, Yohsuke Horiuchi, Takeshi Hayashi, Yoshihide Sehara, Yuji Kato, Yasuko Ohe, Takuya Fukuoka, Hajime Maruyama, Hiroyasu Sano, Yuito Nagamine, Norio Tanahashi Tags: Original Articles Source Type: research

Rosuvastatin Improves Plaque Morphology in Cerebral Embolism Patients with Normal Low-Density Lipoprotein and Severe Aortic Arch Plaque
The effect of rosuvastatin was investigated on complicated aortic arch plaque (CAP) morphology and lipid profiles in acute cerebral embolism (CE) patients with normal low-density lipoprotein-cholesterol (LDL-c) levels. Transesophageal echocardiography (TEE) studies were performed in 56 consecutive CE patients with LDL-c less than 140 mg/dL who were not taking lipid-lowering agents at baseline. CAP observed by TEE was defined as the presence of greater than 4-mm diameter, ulcerated, or mobile aortic plaque. Patients were divided into those with CAP versus without CAP (group A, n = 24, age 69 ± 8 years) and without CA...
Source: Journal of Stroke and Cerebrovascular Diseases - April 15, 2014 Category: Neurology Authors: Kazuyoshi Kaneko, Hiroki Saito, Tetsuya Takahashi, Nobuyuki Kiribayashi, Koki Omi, Toshiki Sasaki, Takeshi Niizeki, Shigeo Sugawara, Masahiro Akasaka, Isao Kubota Tags: Original Articles Source Type: research

Rosuvastatin Ameliorates Early Brain Injury after Subarachnoid Hemorrhage via Suppression of Superoxide Formation and Nuclear Factor-Kappa B Activation in Rats
Source: Journal of Stroke and Cerebrovascular Diseases - February 14, 2014 Category: Neurology Authors: Ken Uekawa, Yu Hasegawa, Mingjie Ma, Takashi Nakagawa, Tetsuji Katayama, Daisuke Sueta, Kensuke Toyama, Keiichiro Kataoka, Nobutaka Koibuchi, Takayuki Kawano, Jun-ichi Kuratsu, Shokei Kim-Mitsuyama Tags: Original Articles Source Type: research